Meeting of the Advisory Committee on Immunization Practices, 45896-45897 [2024-11439]

Download as PDF ddrumheller on DSK120RN23PROD with NOTICES1 45896 Federal Register / Vol. 89, No. 102 / Friday, May 24, 2024 / Notices • High Performance Computing (HPC) 0043, by either of the methods listed below. CDC does not accept comments Thomas Santucci, by email. Director, Division of IT Modernization, Office • Federal eRulemaking Portal: of Technology Policy, Office of Governmenthttps://www.regulations.gov. Follow the wide Policy, General Services Administration. instructions for submitting comments. [FR Doc. 2024–11436 Filed 5–23–24; 8:45 am] • Mail: Ms. Stephanie Thomas, ACIP BILLING CODE 6820–68–P Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia DEPARTMENT OF HEALTH AND 30329–4027. Attn: Docket No. CDC– HUMAN SERVICES 2024–0043. Instructions: All submissions received Agency for Toxic Substances and must include the Agency name and Disease Registry docket number. All relevant comments received in conformance with the [Docket No. ATSDR–2024–0001] https://www.regulations.gov suitability Availability of Three Draft policy will be posted without change to Toxicological Profiles https://www.regulations.gov, including any personal information provided. For Correction access to the docket to read background In notice document 2024–09662, documents or comments received, go to appearing on pages 36820 through https://www.regulations.gov. 36821 in the issue of Friday, May 3, The meeting will be webcast live via 2024, make the following correction: the World Wide Web. The webcast link On page 36820, in the first column, in can be found on the ACIP website at the DATES section, on the second line, https://www.cdc.gov/vaccines/acip/ ‘‘May 3, 2024’’ should read ‘‘August 1, index.html. 2024’’. FOR FURTHER INFORMATION CONTACT: [FR Doc. C1–2024–09662 Filed 5–23–24; 8:45 am] Stephanie Thomas, Committee BILLING CODE 0099–10–D Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and DEPARTMENT OF HEALTH AND Respiratory Diseases, Centers for HUMAN SERVICES Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Centers for Disease Control and Atlanta, Georgia 30329–4027. Prevention Telephone: (404) 639–8836; Email: [Docket No. CDC–2024–0043] ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Meeting of the Advisory Committee on Purpose: The Advisory Committee on Immunization Practices Immunization Practices (ACIP) is AGENCY: Centers for Disease Control and charged with advising the Director, Prevention (CDC), Department of Health Centers for Disease Control and Prevention (CDC), on the use of and Human Services (HHS). ACTION: Notice and request for comment. immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is SUMMARY: In accordance with the mandated to establish and periodically Federal Advisory Committee Act, the review and, as appropriate, revise the Centers for Disease Control and list of vaccines for administration to Prevention (CDC) announces the vaccine-eligible children through the following meeting of the Advisory Vaccines for Children program, along Committee on Immunization Practices with schedules regarding dosing (ACIP). This meeting is open to the interval, dosage, and contraindications public. Time will be available for public to administration of vaccines. Further, comment. under applicable provisions of the DATES: The meeting will be held on June Affordable Care Act and Section 2713 of 26, 2024, from 8 a.m. to 5:10 p.m., EDT, the Public Health Service Act, June 27, 2024, from 8 a.m. to 5:15 p.m., immunization recommendations of EDT, and June 28, 2024, from 8:30 a.m. ACIP that have been approved by the to 12 p.m., EDT (times subject to Director, CDC, and appear on CDC change); see the ACIP website for immunization schedules generally must updates: https://www.cdc.gov/vaccines/ be covered by applicable health plans. acip/). Matters to be Considered: The agenda Written comments must be received will include discussions on influenza between June 3–17, 2024. vaccines, chikungunya vaccine, COVID– 19 vaccines, pneumococcal vaccines, ADDRESSES: You may submit comments, meningococcal vaccines, Human identified by Docket No. CDC–2024– VerDate Sep<11>2014 17:40 May 23, 2024 Jkt 262001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 papillomavirus (HPV) vaccines, Respiratory Syncytial Virus (RSV) vaccines for adults, RSV vaccines for maternal and pediatric populations, a combined diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type B conjugate, and hepatitis B vaccine (Vaxelis®), and dengue vaccine. Recommendation votes are scheduled for influenza vaccines, COVID–19 vaccines, pneumococcal vaccine, Vaxelis®, and RSV vaccines for adults. A Vaccines for Children (VFC) vote is scheduled for Vaxelis®. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https:// www.cdc.gov/vaccines/acip/meetings/ index.html. Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on June 3–17, 2024. Written comments must be received by June 17, 2024. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the E:\FR\FM\24MYN1.SGM 24MYN1 Federal Register / Vol. 89, No. 102 / Friday, May 24, 2024 / Notices meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the June 26–28, 2024, ACIP meeting must submit a request at https://www.cdc.gov/ vaccines/acip/meetings/ between June 3–17, 2024, and no later than 11:59 p.m., EDT, June 17, 2024, according to the instructions provided. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by June 24, 2024. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to three minutes, and each speaker may speak only once per meeting. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–11439 Filed 5–23–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–7075–N] Announcement of the Advisory Panel on Outreach and Education (APOE) Virtual Meeting Centers for Medicare & Medicaid Services (CMS), Health and Human Services (HHS). ACTION: Notice. ddrumheller on DSK120RN23PROD with NOTICES1 AGENCY: I. Background and Charter Renewal Information This notice announces the next meeting of the APOE (the Panel) in accordance with the Federal Advisory Committee Act. The Panel advises and makes recommendations to the Secretary of the U.S. Department of Health and Human Services (HHS) (the SUMMARY: VerDate Sep<11>2014 17:40 May 23, 2024 Jkt 262001 Secretary) and the Administrator of the Centers for Medicare & Medicaid Services (CMS) on opportunities to enhance the effectiveness of consumer education strategies concerning the Health Insurance Marketplace®, Medicare, Medicaid, and the Children’s Health Insurance Program (CHIP). This meeting is open to the public. DATES: Meeting Date: Thursday, June 27, 2024 from 12 p.m. to 5 p.m. eastern daylight time (e.d.t). Deadline for Meeting Registration, Presentations, Special Accommodations, and Comments: Thursday, June 13, 2024 5 p.m. (e.d.t). ADDRESSES: Meeting Location: Virtual. All those who RSVP will receive the link to attend. Presentations and Written Comments: Presentations and written comments should be submitted to: Walt Gutowski, Designated Federal Official (DFO), Office of Communications, Centers for Medicare & Medicaid Services, 7500 Security Boulevard, Mailstop S1–04–08, Baltimore, MD 21244–1850, 410–786– 6818, or via email at APOE@ cms.hhs.gov. Registration: Persons wishing to attend this meeting must register at the website https://CMS-APOEJune2024.rsvpify.com or by contacting the DFO listed in the FOR FURTHER INFORMATION CONTACT section of this notice, by the date listed in the DATES section of this notice. Individuals requiring sign language interpretation or other special accommodations should contact the DFO at the address listed in the ADDRESSES section of this notice by the date listed in the DATES section of this notice. FOR FURTHER INFORMATION CONTACT: Walt Gutowski, Designated Federal Official, Office of Communications, 7500 Security Boulevard, Mailstop S1–04–08, Baltimore, MD 21244–1850, 410–786– 6818, or via email at APOE@ cms.hhs.gov. Additional information about the APOE is available at: https:// www.cms.gov/Regulations-andGuidance/Guidance/FACA/APOE. Press inquiries are handled through the CMS Press Office at (202) 690–6145. SUPPLEMENTARY INFORMATION: A. Background The Advisory Panel for Outreach and Education (APOE) (the Panel) is governed by the provisions of the Federal Advisory Committee Act (FACA) (Pub. L. 92–463), as amended (5 PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 45897 U.S.C. appendix 2), which sets forth standards for the formation and use of federal advisory committees. The Panel is authorized by section 1114(f) of the Social Security Act (the Act) (42 U.S.C. 1314(f)) and section 222 of the Public Health Service Act (42 U.S.C. 217a). The Panel, which was first chartered in 1999, advises and makes recommendations to the Secretary of the U.S. Department of Health and Human Services (the Department) and the Administrator of the Centers for Medicare & Medicaid Services (CMS) on the effective implementation of national Medicare, Medicaid, Children’s Health Insurance Program (CHIP) and Health Insurance Marketplace outreach and education programs. The APOE has focused on a variety of laws, including the Medicare Modernization Act of 2003 (Pub. L. 108– 173), and the Affordable Care Act (Patient Protection and Affordable Care Act, (Pub.L. 111–148) and Health Care and Education Reconciliation Act of 2010 (Pub.L. 111–152)). The APOE helps the Department determine the best communication channels and tactics for various programs and priorities, as well as new rules and laws. In the coming years, we anticipate the American Rescue Plan (Pub. L. 117–2), the Inflation Reduction Act of 2022 (Pub.L. 117–169), and the SUPPORT for Patients and Communities Act (SUPPORT) Act (Pub.L. 115–271) will be some of the topics the Panel will discuss. The Panel will provide feedback to CMS staff on outreach and education strategies, communication tools and messages and how to best reach minority, vulnerable and Limited English Proficiency populations. B. Charter Renewal The Panel’s charter was renewed on January 19, 2023, and will terminate on January 19, 2025, unless renewed by appropriate action. The Charter can be found at https://www.cms.gov/ regulations-and-guidance/guidance/ faca/apoe. In accordance with the renewed charter, the APOE will advise the Secretary and the CMS Administrator concerning optimal strategies for the following: • Developing and implementing education and outreach programs for individuals enrolled in, or eligible for, Medicare, Medicaid, the CHIP, and coverage available through the Health Insurance Marketplace® and other CMS programs. • Enhancing the federal government’s effectiveness in informing Medicare, Medicaid, CHIP, or the Health Insurance Marketplace® consumers, issuers, E:\FR\FM\24MYN1.SGM 24MYN1

Agencies

[Federal Register Volume 89, Number 102 (Friday, May 24, 2024)]
[Notices]
[Pages 45896-45897]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11439]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2024-0043]


Meeting of the Advisory Committee on Immunization Practices

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC) announces the 
following meeting of the Advisory Committee on Immunization Practices 
(ACIP). This meeting is open to the public. Time will be available for 
public comment.

DATES: The meeting will be held on June 26, 2024, from 8 a.m. to 5:10 
p.m., EDT, June 27, 2024, from 8 a.m. to 5:15 p.m., EDT, and June 28, 
2024, from 8:30 a.m. to 12 p.m., EDT (times subject to change); see the 
ACIP website for updates: https://www.cdc.gov/vaccines/acip/).
    Written comments must be received between June 3-17, 2024.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0043, by either of the methods listed below. CDC does not accept 
comments by email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for 
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, 
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2024-0043.
    Instructions: All submissions received must include the Agency name 
and docket number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov.
    The meeting will be webcast live via the World Wide Web. The 
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management 
Specialist, Advisory Committee on Immunization Practices, National 
Center for Immunization and Respiratory Diseases, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, 
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Purpose: The Advisory Committee on Immunization Practices (ACIP) is 
charged with advising the Director, Centers for Disease Control and 
Prevention (CDC), on the use of immunizing agents. In addition, under 
42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children program, along with schedules regarding dosing interval, 
dosage, and contraindications to administration of vaccines. Further, 
under applicable provisions of the Affordable Care Act and Section 2713 
of the Public Health Service Act, immunization recommendations of ACIP 
that have been approved by the Director, CDC, and appear on CDC 
immunization schedules generally must be covered by applicable health 
plans.
    Matters to be Considered: The agenda will include discussions on 
influenza vaccines, chikungunya vaccine, COVID-19 vaccines, 
pneumococcal vaccines, meningococcal vaccines, Human papillomavirus 
(HPV) vaccines, Respiratory Syncytial Virus (RSV) vaccines for adults, 
RSV vaccines for maternal and pediatric populations, a combined 
diphtheria and tetanus toxoids and acellular pertussis, inactivated 
poliovirus, Haemophilus influenzae type B conjugate, and hepatitis B 
vaccine (Vaxelis[supreg]), and dengue vaccine. Recommendation votes are 
scheduled for influenza vaccines, COVID-19 vaccines, pneumococcal 
vaccine, Vaxelis[supreg], and RSV vaccines for adults. A Vaccines for 
Children (VFC) vote is scheduled for Vaxelis[supreg]. Agenda items are 
subject to change as priorities dictate. For more information on the 
meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
    Meeting Information: The meeting will be webcast live via the World 
Wide Web. For more information on ACIP, please visit the ACIP website: 
https://www.cdc.gov/vaccines/acip/.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Please note that 
comments received, including attachments and other supporting 
materials, are part of the public record and are subject to public 
disclosure. Comments will be posted on https://www.regulations.gov. 
Therefore, do not include any information in your comment or supporting 
materials that you consider confidential or inappropriate for public 
disclosure. If you include your name, contact information, or other 
information that identifies you in the body of your comments, that 
information will be on public display. CDC will review all submissions 
and may choose to redact, or withhold, submissions containing private 
or proprietary information such as Social Security numbers, medical 
information, inappropriate language, or duplicate/near-duplicate 
examples of a mass-mail campaign. CDC will carefully consider all 
comments submitted into the docket.
    Written Public Comment: The docket will be opened to receive 
written comments on June 3-17, 2024. Written comments must be received 
by June 17, 2024.
    Oral Public Comment: This meeting will include time for members of 
the public to make an oral comment. Oral public comment will occur 
before any scheduled votes, including all votes relevant to the ACIP's 
Affordable Care Act and Vaccines for Children Program roles. Priority 
will be given to individuals who submit a request to make an oral 
public comment before the

[[Page 45897]]

meeting according to the procedures below.
    Procedure for Oral Public Comment: All persons interested in making 
an oral public comment at the June 26-28, 2024, ACIP meeting must 
submit a request at https://www.cdc.gov/vaccines/acip/meetings/ between June 3-17, 2024, and no later than 11:59 p.m., EDT, 
June 17, 2024, according to the instructions provided.
    If the number of persons requesting to speak is greater than can be 
reasonably accommodated during the scheduled time, CDC will conduct a 
lottery to determine the speakers for the scheduled public comment 
session. CDC staff will notify individuals regarding their request to 
speak by email by June 24, 2024. To accommodate the significant 
interest in participation in the oral public comment session of ACIP 
meetings, each speaker will be limited to three minutes, and each 
speaker may speak only once per meeting.
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-11439 Filed 5-23-24; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.